Mesoblast shares tank after Novartis abandons a partnership for the biotech's potential Covid-19 treatment

Nicole DeFeudis

Editor

Novartis offered up $25 million in cash last November for the rights to Mesoblast’s potential cell therapy for Covid-19. But after a Phase III flunk …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mesoblast shares tank after Novartis abandons a partnership for the biotech's potential Covid-19 treatment

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

Mesoblast shares tank af­ter No­var­tis aban­dons a part­ner­ship for the biotech's po­ten­tial Covid-19 treat­ment

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Mesoblast shares tank after Novartis abandons a partnership for the biotech's potential Covid-19 treatment